Literature DB >> 28577230

The financial performance of the health care industry: a global, regional and industry specific empirical investigation.

Gregor Dorfleitner1, Felix Rößle2.   

Abstract

This article analyzes the financial (out-) performance of all listed health care companies. The health care sector outperformed the market in the period from 2000 to June 2015. The performance was driven by companies from Americas, and Asia as well as companies from the pharmaceuticals sub-segment. Additionally, bull periods appear to be the main driver for the outperformance. Euro-based investors can expect different outcomes of their investments to those of USD investors. However, the main trends remain unchanged.

Entities:  

Keywords:  Four-factor model; Health economics; Stock performance

Mesh：

Year:  2017        PMID： 28577230     DOI： 10.1007/s10198-017-0904-8

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN： 1618-7598


  17 in total

1.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

Review 2.  Can the pharmaceutical industry reduce attrition rates?

Authors:  Ismail Kola; John Landis
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

Review 3.  Returns to R&D on new drug introductions in the 1980s.

Authors:  H G Grabowski; J M Vernon
Journal:  J Health Econ       Date:  1994-12       Impact factor: 3.883

4.  Direct costs of Alzheimer's disease in Germany.

Authors:  Peter Kiencke; Dietmar Daniel; Christine Grimm; Reinhard Rychlik
Journal:  Eur J Health Econ       Date:  2010-07-18

5.  The return on investment in health care: from 1980 to 2000.

Authors:  Bryan R Luce; Josephine Mauskopf; Frank A Sloan; Jan Ostermann; L Clark Paramore
Journal:  Value Health       Date:  2006 May-Jun       Impact factor: 5.725

6.  Spending on new drug development1.

Authors:  Christopher Paul Adams; Van Vu Brantner
Journal:  Health Econ       Date:  2010-02       Impact factor: 3.046

Review 7.  The productivity crisis in pharmaceutical R&D.

Authors:  Fabio Pammolli; Laura Magazzini; Massimo Riccaboni
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

8.  Innovation in the pharmaceutical industry: New estimates of R&D costs.

Authors:  Joseph A DiMasi; Henry G Grabowski; Ronald W Hansen
Journal:  J Health Econ       Date:  2016-02-12       Impact factor: 3.883

Review 9.  [Dementia in advanced age: estimating incidence and health care costs].

Authors:  H Bickel
Journal:  Z Gerontol Geriatr       Date:  2001-04       Impact factor: 1.281

Review 10.  How the effects of aging and stresses of life are integrated in mortality rates: insights for genetic studies of human health and longevity.

Authors:  Anatoliy I Yashin; Konstantin G Arbeev; Liubov S Arbeeva; Deqing Wu; Igor Akushevich; Mikhail Kovtun; Arseniy Yashkin; Alexander Kulminski; Irina Culminskaya; Eric Stallard; Miaozhu Li; Svetlana V Ukraintseva
Journal:  Biogerontology       Date:  2015-08-18       Impact factor: 4.277
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.